Adaptimmune Therapeutics Plc - ADR

NASDAQ:ADAP

0.25

+0.01 (+3.14%)

4:44:06 PM EDT: $0.25 0.00 (0.44%)

Market Cap (Intraday)	66.49M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$11.19 Million
Adjusted EPS	-$0.05

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Adaptimmune Therapeutics Plc - ADR Stock, NASDAQ:ADAP

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX

United Kingdom

Phone: +44.1235.430000

Number of Employees: 449

http://www.adaptimmune.com

Description

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.